Elisa Rush Port

Elisa Rush Port, MD, FACS
Dr. Elisa Rush Port
Born New York City
Education Dartmouth College, Hanover, New Hampshire; University of California, Los Angeles; Mount Sinai School of Medicine
Years active 1992 - Present
Known for Chief, Breast Surgery at the Icahn School of Medicine at Mount Sinai, author of The New Generation Breast Cancer Book: How to Navigate Your Diagnosis and Treatment Options-and Remain Optimistic-in an Age of Information Overload
Medical career
Profession Surgical oncology
Institutions Cedars-Sinai Medical Center, Los Angeles; Memorial Sloan Kettering Cancer Center, New York; Mount Sinai School of Medicine, New York City; Weill Cornell Medical College, Cornell University Surgery; Memorial Hospital for Cancer and Allied Diseases, New York City; Long Island Jewish Medical Center, New Hyde Park, New York
Specialism Breast cancer
Research Triple negative breast cancer, Sentinel node diagnostics
Website www.mountsinai.org/profiles/elisa-r-port

Elisa Rush Port, MD, FACS, is Associate Professor of Surgery at the Icahn School of Medicine at Mount Sinai Hospital, as well as cofounder and director of the Dubin Breast Center at the Tisch Cancer Institute at Mount Sinai Health System, since 2010.[1][2][3] She has received four research grants, has served as an investigator or co-investigator on 15 clinical trials, published 44 peer-reviewed articles, and published a total of 12 book chapters and books. She is considered "a leading expert" in sentinel-node biopsy, a diagnostic method that determines cancer stages based on spread to regional lymph nodes, nipple sparing mastectomy, and the use of MRI for breast cancer.[4]

Biography

Port was born in New York City and grew up in San Diego, majored in French and Spanish at Dartmouth College (1986), received her MD at Mount Sinai School of Medicine (1992), performed an internship at Cedars-Sinai Medical Center, general surgery residencies at Cedars-Sinai Medical Center and Long Island Jewish Medical Center, and a research fellowship at Memorial Sloan Kettering Cancer Center (1994-1996), where she was a staff breast cancer surgeon from 1999 to 2010. In 2010 she co-founded the Dubin Breast Center at Mount Sinai.[5]

She is among a group of surgical oncologists like Dr. Laura J. Esserman, who challenges the one-size-fits-all approach to treatment. In a 2015 New York Times profile, Esserman's approach to screening and when and how it should be applied to those at risk for breast cancer was framed as being slow to receive acceptance in the medical community. Esserman is not without supporters and researchers like Port, who was quoted in the same article: "Laura is one of the people who's actively engaged in research in this area and will help us push the field forward to determine whether or not there is a group of people for whom surveillance will be appropriate."[6]

This approach to diagnostics and treatment is highlighted in Port's The New Generation Breast Cancer Book.[7] In an editorial review, Edie Falco wrote that the book "[…] helps you sort through all the information you've gathered, clarify the terminology, consider the options, and make the right decisions for your unique case."[8]

Port is frequently sourced in media, including NPR, The New York Times, television news networks, and digital and print magazines.[9]

She is married to Jeffrey L. Port, MD, a thoracic surgeon at Weill Cornell Medicine/NewYork–Presbyterian Hospital. They have two children.[10]

Research

Port has published a large body of work on sentinel-node diagnostics, used to determine a patient's cancer stage, and researched PET scanning for pre-operative assessment of breast cancer. She conducted a Phase I study, in collaboration with Dr. Andrew Dannenberg and Dr. Clifford Hudis at Memorial Sloan Kettering Cancer Center, on the inhibition of the enzymes COX-2 and aromatase in breast cancer and mechanisms of its drug resistance.[11]

Port's current research work involves a collaboration with Dr. Hanna Irie on triple negative breast cancer. Their work is aimed at better understanding and treatments of triple negative breast cancer and mechanisms of its drug resistance.[12]

Other recent work addresses the benefits of screening mammography. With collaborators, the work has shown that patients who undergo mammograms are less likely to require more aggressive surgical or medical treatments as a result of early detection.

She has been a vocal critic of the current United States Preventive Services Task Force guideline that now classifies mammograms as optional for women between 40 and 49 years of age. According to Dr. Julie Margenthaler, a breast surgeon with the Washington University School of Medicine and Chair of the ASBrS Communication Committee, the controversy appears to be a result of conflicting data from studies, as well as a focus on incidence rates, possibly without placing equal value on the stage of a patient's cancer when first diagnosed.[13][14][15][16][17] Regarding this debate, Port co-authored a New York Times op-ed titled "Why the Annual Mammogram Matters".

Port's funding has come in part from the Susan G. Komen Breast Cancer Foundation, the Breast Cancer Research Foundation, a Breast Cancer Alliance Exceptional Project Grant, and the National Institutes of Health.

Grants

Role Title Funding source/Identifier
Principal Investigator The role of FDG-PET scanning in the pre-operative management of patients with primary and recurrent breast carcinoma (IRB #01-134) Susan G. Komen Breast Cancer Foundation
Principal Investigator A phase I pharmacodynamic study of COX-2 inhibition and aromatase activity in breast cancer (IRB #03-027) NIH N01 CN0351 12-76, MD Anderson Prime Awardee
Co-Principal Investigator with Hanna Yoko Irie, MD, PhD Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer Breast Cancer Research Foundation, NCT02247037, GCO 14-0686
Co-Principal Investigator with Hanna Yoko Irie, MD, PhD Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer (extension of above-listed research) Breast Cancer Alliance Exceptional Project Grant, NCT02247037, GCO 14-0686

Clinical trials

Partial list

Role Title Funding source/Identifier
Principal Investigator #01-134: The role of FDG-PET scanning in the pre-operative management of patients with primary and recurrent breast carcinoma Susan G. Komen Breast Cancer Foundation
Principal Investigator #03-027 An exploratory, open-label phase I pharmacodynamic study of COX-2 inhibition with Celocoxib (Celebrex) and aromatase activity in breast cancer NCI-DCP
Principal Investigator #14-0686, Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer Breast Cancer Research Foundation, BCA

Professional affiliations

Honors and awards

  • Mother of the Year Award, American Cancer Society, 2013[21]

Articles

Partial list of peer-reviewed articles:

  • Simon Fitzgerald, Anya Romanoff, Almog Cohen, Hank Schmidt, Christina Weltz, Ira J. Bleiweiss, Shabnam Jaffer, Elisa R. Port, "Close and Positive Lumpectomy Margins are Associated with Similar Rates of Residual Disease with Additional Surgery". Annals of Surgical Oncology, December 2016, Volume 23, Issue 13, pp 4270-4276 PMID 27581606
  • Anup Sood, Alexandra M. Miller, Edi Brogi, Yunxia Sui, Joshua Armenia, Elizabeth McDonough AlbertoSantamaria-Pang, Sean Carlin, Aleksandra Stamper, Carl Campos, Zhengyu Pang, Qing Li, Elisa Port, Thomas G. Graeber, Nikolaus Schultz, Fiona Ginty, Steven M. Larson, and Ingo K. Mellinghoff. "Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism". Journal of Clinical Investigation, e87030, May 5, 2016 PMID 27182557
  • William M. Sikov, Donald A. Berry, Charles M. Perou, Baljit Singh, Constance T. Cirrincione, Sara M. Tolaney, Charles S. Kuzma, Timothy J. Pluard, George Somlo, Elisa R. Port, Mehra Golshan, Jennifer R. Bellon, Deborah Collyar, Olwen M. Hahn, Lisa A. Carey, Clifford A. Hudis, Eric P. Winer. "Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in Stage II-III triple-negative breast cancer: CALGB 40603 (Alliance)". Journal of Clinical Oncology, 2014. PMID 25092775
  • Schmidt H., Port E. "Commentary on Kaur et al. Sentinel Lymph Node Biopsy in Patients with Previous Ipsilateral Complete Axillary Lymph Node Dissection". Breast Diseases: A Year Book Quarterly, 2012; 23(1):72-73. PMID 20593244
  • Palaskas N., Larson S., Schultz N., Komisopoulou E., Wong D., Rohle D., Campos C., Yannuzzi N., Osborne J., Linkov I., Kastenhuber E., Taschereau R., Plaisier S.B., Tran C., Heguy A., Wu H., Sander C., Phelps M.E., Brennan C.W., Port E.R., Huse J.T., Graeber T.G. "18F-fluorodeoxy-glucose Positron Emission Tomography (18FDG-PET) Marks Basal-Like Human Breast Cancer with MYC Overexpression". AACR 2011 March 17. PMID 21646475
  • Port E.R., Patil S., Stempel M., Morrow M., Cody H.S. "The Number of Nodes Removed in Sentinel Node-Negative Breast Cancer Patients is Significantly Related to Patient Age and Tumor Size: A New Source of Bias in Morbidity Assessment?" Cancer 2010 Feb 11 (Epub ahead of print). PMID 21646475
  • Chung A., Schoder H., Sampson M., Morrow M., Port E.R. "Incidental Breast Lesions Identified by 18F-Fluorodeoxyglucose-Positron Emission Tomography". Ann Surg Oncol 2010 Feb 17 (Epub ahead of print). PMID 20162459
  • Garwood E.R., Kumar A.S., Baehner F.L., Moore D.H., Au A., Flowers C., Troyan S., Garber J., Olopade O., Hylton N., Port E.R., Campbell M.C., Esserman L.J. "Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer". Breast Can Res Treat 2010;119(1):137-144. PMID 19728082
  • Karam A.K., Hsu M., Patil S., Stempel M., Traina T.A., Ho A.Y., Cody H.S., Port E.R., Morrow M., Gemignani M.L. "Predictors of completion axillary lymph node dissection in patients with positive sentinel lymph nodes". Ann Surg Oncol 2009 Jul;16(7):1952-8. PMID 19381724
  • Disa J.J., Port E.R. "More than 200,000 women will be diagnosed with breast cancer in 2008". Cancer J. 2008 Jul-Aug; 14(4):214-5. PMID 18677127

Books and book chapters

Partial list:

  • The New Generation Breast Cancer Book: How to Navigate Your Diagnosis and Treatment Options-and Remain Optimistic-in an Age of Information Overload, Ballantine Books, 2015 ISBN 1101883154
  • Port, ER. Chapter 17: "Commentary – Breast Cancer Therapeutics". In: Silberman H., Silberman A.W. (eds). Principles and Practice of Surgical Oncology, 2nd ed. Lippincott Williams & Wilkins, Philadelphia, 2010:356. ISBN 0781765463
  • Port E.R., Morris E.A. Chapter 35: "Breast MRI". In: Kuerer H.M. (ed). Kuerer's Breast Surgical Oncology, 1st ed. McGraw Hill, New York, 2009 ISBN 0071601767

References

  1. ↑ "One Surgeons' Perspective". Women's Voices for Change. Retrieved 11 June 2018.
  2. ↑ "Elisa R. Port, MD, FACS, Named Chief of Breast Surgery at Mount Sinai School of Medicine". Mt. Sinai Newsroom.
  3. ↑ "Why Dr. Eva Andersson-Dubin Founded the Dubin Breast Cancer Center". Gotham Magazine. Retrieved 11 June 2018.
  4. ↑ "Chief of Breast Surgery, Mount Sinai; Co-Director, Dubin Breast Center". Author Bio. Huffington Post. Retrieved 11 June 2018.
  5. ↑ "Social Circles Profile". Modern Luxury.
  6. ↑ "A Breast Cancer Surgeon Who Keeps Challenging the Status Quo". The New York Times. Retrieved 11 June 2018.
  7. ↑ "Surgeon Seeks to Help Women Navigate Breast Cancer Treatment". Shots: Health News From NRP. Retrieved 11 June 2018.
  8. ↑ The New Generation Breast Cancer Book: How to Navigate Your Diagnosis and Treatment Options-and Remain Optimistic-in an Age of Information Overload. Amazon. ASIN 1101883154.
  9. ↑ "Author Biography". Penguin Random House. Retrieved 11 June 2018.
  10. ↑ "Monday Observations". New York Social Diary.
  11. ↑ "Elisa Port, MD Profile". Breast Cancer Alliance. Retrieved 12 June 2018.
  12. ↑ "Elisa Port, Researcher". Breast Cancer Research Foundation. Retrieved 12 June 2018.
  13. ↑ "Screening Mammography Lowers Breast Cancer Patients' Needs for Aggressive Treatment, Study Finds". Forbes. Retrieved 12 June 2018.
  14. ↑ "Breast cancer screening linked to lower stage at diagnosis, less intensive treatment". Healio.
  15. ↑ "Period, end of discussion? Not so fast. Breast surgeon sidesteps mammography screening debate". Breast Cancer Consortium. Retrieved 18 June 2018.
  16. ↑ "Regular Mammograms Mean Earlier Breast Cancer Diagnosis and Less Aggressive Treatment". American Society of Breast Surgeons. Retrieved 18 June 2018.
  17. ↑ "New mammogram guidelines draw criticism". MSNBC. Retrieved 18 June 2018.
  18. ↑ "Regular Mammograms Mean Earlier Breast Cancer Diagnosis and Less Aggressive Treatment". American Society of Breast Surgeons. Retrieved 12 June 2018.
  19. ↑ "Advisory Board". Women's Voices for Change.
  20. ↑ "World-class science highlights 58th Annual Cancer Symposium" (PDF). Newsletter of the Society of Surgical Oncology. SSO News. Retrieved 12 June 2018.
  21. ↑ "Mother of the year award, American Cancer Society". Retrieved 15 July 2018.

See also

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.